Pathogenetic insights from the treatment of rheumatoid arthritis (Q39371679)

11 September 2017

1 reference

title

Pathogenetic insights from the treatment of rheumatoid arthritis (English)

1 reference

11 September 2017

0 references

1 reference

2

Georg Schett

1 reference

11 September 2017

Iain B McInnes

1

1 reference

PubMed ID

28612747

11 September 2017

language of work or name

English

0 references

publication date

1 June 2017

1 reference

11 September 2017

1 reference

11 September 2017

389

1 reference

11 September 2017

2328-2337

1 reference

11 September 2017

10086

1 reference

Mechanisms involved in triggering rheumatoid arthritis

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Genetics of rheumatoid arthritis contributes to biology and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome-Wide DNA Microarray

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Is IL-1 a good therapeutic target in the treatment of arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Cytokines in rheumatoid arthritis - shaping the immunological landscape

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Cytokine-producing B lymphocytes-key regulators of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Forget personalised medicine and focus on abating disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Stromal cells in chronic inflammation and tertiary lymphoid organ formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Epigenetic contributions in the development of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

How antirheumatic drugs protect joints from damage in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

C-reactive protein, fibrinogen, and cardiovascular disease prediction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Blockade of TNF-α rapidly inhibits pain responses in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Immune suppression and immune activation in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Cigarette smoking and smoking cessation in relation to risk of rheumatoid arthritis in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

Expanding antigen-specific regulatory networks to treat autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931472-1

7 January 2021

10.1016/S0140-6736(17)31472-1

Identifiers

DOI

1 reference

11 September 2017

1 reference

PubMed ID

28612747